114 related articles for article (PubMed ID: 19058059)
1. The influence of smoking on bone loss and response to nasal estradiol.
Bjarnason NH; Nielsen TF; Jørgensen HL; Christiansen C
Climacteric; 2009 Feb; 12(1):59-65. PubMed ID: 19058059
[TBL] [Abstract][Full Text] [Related]
2. Oral hormone therapy with 17beta-estradiol and 17beta-estradiol in combination with norethindrone acetate in the prevention of bone loss in early postmenopausal women: dose-dependent effects.
Greenwald MW; Gluck OS; Lang E; Rakov V
Menopause; 2005; 12(6):741-8. PubMed ID: 16278618
[TBL] [Abstract][Full Text] [Related]
3. Three-year follow-up of the use of transdermal 17beta-estradiol matrix patches for the prevention of bone loss in early postmenopausal women.
Delmas PD; Pornel B; Felsenberg D; Stakkestad JA; Radowicki S; Garnero P; Hardy P; Dain MP; Petitier B;
Am J Obstet Gynecol; 2001 Jan; 184(2):32-40. PubMed ID: 11174476
[TBL] [Abstract][Full Text] [Related]
4. Influence of modified transdermal hormone replacement therapy on the concentrations of hormones, growth factors, and bone mineral density in women with osteopenia.
Stanosz S; Zochowska E; Safranow K; Sieja K; Stanosz M
Metabolism; 2009 Jan; 58(1):1-7. PubMed ID: 19059524
[TBL] [Abstract][Full Text] [Related]
5. Low doses of estradiol in combination with gestodene to prevent early postmenopausal bone loss.
Bjarnason NH; Byrjalsen I; Hassager C; Haarbo J; Christiansen C
Am J Obstet Gynecol; 2000 Sep; 183(3):550-60. PubMed ID: 10992173
[TBL] [Abstract][Full Text] [Related]
6. Effect of microdose transdermal 17beta-estradiol compared with raloxifene in the prevention of bone loss in healthy postmenopausal women: a 2-year, randomized, double-blind trial.
Schaefers M; Muysers C; Alexandersen P; Christiansen C
Menopause; 2009; 16(3):559-65. PubMed ID: 19423999
[TBL] [Abstract][Full Text] [Related]
7. An estradiol matrix transdermal system for the prevention of postmenopausal bone loss.
McKeever C; McIlwain H; Greenwald M; Gupta N; Jayawardene S; Huels G; Roberts M
Clin Ther; 2000 Jul; 22(7):845-57. PubMed ID: 10945511
[TBL] [Abstract][Full Text] [Related]
8. Changes in bone markers after once-weekly low-dose alendronate in postmenopausal women with moderate bone loss.
Choi HJ; Im JA; Kim SH
Maturitas; 2008 Jun; 60(2):170-6. PubMed ID: 18572334
[TBL] [Abstract][Full Text] [Related]
9. Percutaneous estrogen in prevention of early postmenopausal bone loss in Chinese women.
Sun A; Lin S; Yu W; Qin M; Chen F; Zhang Y; Wei Y; de Lignieres B
Chin Med J (Engl); 2002 Dec; 115(12):1790-5. PubMed ID: 12622925
[TBL] [Abstract][Full Text] [Related]
10. Effects on serum lipid and leptin levels of three different doses of norethisterone continuously combined with a fixed dose of 17beta-estradiol for nasal administration in postmenopausal women: a controlled, double-blind study.
Castelo-Branco C; Palacios S; Vázquez F; Villero J; Ferrer J; Ascaso C; Balasch J
Fertil Steril; 2007 Aug; 88(2):383-9. PubMed ID: 17561009
[TBL] [Abstract][Full Text] [Related]
11. The influence of thinness and smoking on bone loss and response to hormone replacement therapy in early postmenopausal women.
Bjarnason NH; Christiansen C
J Clin Endocrinol Metab; 2000 Feb; 85(2):590-6. PubMed ID: 10690860
[TBL] [Abstract][Full Text] [Related]
12. Dose effects of oral estradiol on bone mineral density in Japanese women with osteoporosis.
Mizunuma H; Taketani Y; Ohta H; Honjo H; Gorai I; Itabashi A; Shiraki M
Climacteric; 2010 Feb; 13(1):72-83. PubMed ID: 19591010
[TBL] [Abstract][Full Text] [Related]
13. Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial.
Stoch SA; Saag KG; Greenwald M; Sebba AI; Cohen S; Verbruggen N; Giezek H; West J; Schnitzer TJ
J Rheumatol; 2009 Aug; 36(8):1705-14. PubMed ID: 19487264
[TBL] [Abstract][Full Text] [Related]
14. Effects of drospirenone/estrogen combinations on bone metabolism.
Christiansen C
Climacteric; 2005 Oct; 8 Suppl 3():35-41. PubMed ID: 16203654
[TBL] [Abstract][Full Text] [Related]
15. Double-blind placebo-controlled study of testosterone patch therapy on bone turnover in men with borderline hypogonadism.
Merza Z; Blumsohn A; Mah PM; Meads DM; McKenna SP; Wylie K; Eastell R; Wu F; Ross RJ
Int J Androl; 2006 Jun; 29(3):381-91. PubMed ID: 16390499
[TBL] [Abstract][Full Text] [Related]
16. The effect on cartilage of different forms of application of postmenopausal estrogen therapy: comparison of oral and transdermal therapy.
Ravn P; Warming L; Christgau S; Christiansen C
Bone; 2004 Nov; 35(5):1216-21. PubMed ID: 15542048
[TBL] [Abstract][Full Text] [Related]
17. Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments.
Giusti A; Barone A; Pioli G; Girasole G; Siccardi V; Palummeri E; Bianchi G
Nephrol Dial Transplant; 2009 May; 24(5):1472-7. PubMed ID: 19075192
[TBL] [Abstract][Full Text] [Related]
18. Double-blind placebo-controlled study to evaluate the effect of pro-juven progesterone cream on atherosclerosis and bone density.
Benster B; Carey A; Wadsworth F; Griffin M; Nicolaides A; Studd J
Menopause Int; 2009 Sep; 15(3):100-6. PubMed ID: 19723679
[TBL] [Abstract][Full Text] [Related]
19. Postmenopausal oral estrogen therapy and blood pressure in normotensive and hypertensive subjects: the Estrogen in the Prevention of Atherosclerosis Trial.
Steiner AZ; Hodis HN; Lobo RA; Shoupe D; Xiang M; Mack WJ
Menopause; 2005; 12(6):728-33. PubMed ID: 16278616
[TBL] [Abstract][Full Text] [Related]
20. Acute and long-term estradiol kinetics in smoking postmenopausal women.
Bjarnason NH; Jørgensen HL; Christiansen C
Climacteric; 2012 Oct; 15(5):449-54. PubMed ID: 22191426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
